Table 1.
Demographics and comorbidities at baseline in the 2 groups.
| Demographics and Comorbidities | No therapy with ACEI/ARB | Therapy with ACEI/ARB | P-value |
|---|---|---|---|
| Number of patients | 84 | 36 | |
| Age | 65.5 (19–88) | 65.5 (42–80) | .09 |
| Gender | Female—39 (46.4%) | Female—21 (58.3%) | .23 |
| Male—45 (53.6%) | Male—15 (41.7%) | ||
| Race | 100% Caucasian | 100% Caucasian | |
| Obesity | No—76 (90.5%) | No—27 (75.0%) | .02 |
| Yes—8 (9.5%) | Yes—9 (25.0%) | ||
| Cardiovascular diseases | No—59 (70.2%) | No—18 (50.0%) | .03 |
| Yes—25 (29.8%) | Yes—18 (50.0%) | ||
| Diabetes | No—58 (69.0%) | No—21 (58.3%) | 0.25 |
| Yes—26 (31.0%) | Yes—15 (41.7%) | ||
| Hypertension | No—36 (42.9%) | No—5 (13.9%) | .002 |
| Yes—48 (57.1%) | Yes—31 (86.1%) | ||
| CKD | No—40 (47.6%) | No—10 (27.8%) | .04 |
| Yes—44 (52.4%) | Yes—26 (72.2%) |
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, CKD = chronic kidney disease.